Lucid Diagnostics Labs LLC

Lucid Diagnostics Labs LLC was paid $2.97M by Medicaid between Apr 2019 and Dec 2024, across 56 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 67% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Ohio

Rank by total paid#28 of 116

Median peer was paid$313K

This provider vs. median9.5×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2019	4,749	$15K
2020	26,182	$1.36M
2021	39,528	$1.14M
2022	13,405	$249K
2023	256	$7K
2024incomplete	6,611	$194K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	67%	30,894	27,197	$1.99M
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	16%	30,069	26,475	$481K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	7.2%	14,242	12,349	$215K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	5.2%	4,315	3,644	$154K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	3.3%	4,320	3,599	$99K
80050	General health panel	<1%	127	103	$3K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	205	175	$3K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	205	175	$3K
86480		<1%	73	63	$2K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	98	89	$1K
80361		<1%	239	78	$1K
80074		<1%	145	126	$1K

44 more codes

83992		<1%	239	$953.19
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	143	$951.36
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	122	$872.62
80364		<1%	177	$784.00
80372		<1%	239	$716.22
80373		<1%	239	$716.22
80357		<1%	239	$716.22
80346		<1%	144	$697.00
80355		<1%	239	$677.79
80354		<1%	243	$668.43
80356		<1%	239	$668.43
80365		<1%	239	$668.43
80348		<1%	243	$668.43
80345		<1%	239	$668.43
80359		<1%	239	$668.43
80358		<1%	239	$668.43
80324		<1%	239	$668.43
80353		<1%	239	$668.43
80349		<1%	239	$668.43
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	150	$620.76
82607		<1%	152	$540.63
86780		<1%	118	$471.49
84481		<1%	105	$416.72
80347		<1%	43	$312.34
82248		<1%	136	$180.74
36415	Collection of venous blood by venipuncture	<1%	142	$168.80
80369		<1%	43	$148.54
80360		<1%	43	$148.54
80337		<1%	43	$148.54
80338		<1%	43	$148.54
80371		<1%	43	$148.54
80367		<1%	43	$148.54
80368		<1%	43	$148.54
80334		<1%	43	$140.00
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	61	$137.70
80323		<1%	42	$129.35
80053	Comprehensive metabolic panel	<1%	31	$128.42
80366		<1%	43	$126.00
84436		<1%	104	$102.82
84443	Thyroid stimulating hormone (TSH)	<1%	31	$98.50
80339		<1%	43	$84.00
86592		<1%	22	$16.59
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	0%	38	$0.00
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	0%	15	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialNARAHARI, MADDY (OWNER)